Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
PremiumPress ReleasesData from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
1M ago
Ascendis Pharma presents data from Phase 2 ACcomplisH Trial of TransCon CNP
PremiumThe Fly
Ascendis Pharma presents data from Phase 2 ACcomplisH Trial of TransCon CNP
1M ago
Ascendis Pharma Updates Corporate Financial Strategy
PremiumCompany Announcements
Ascendis Pharma Updates Corporate Financial Strategy
1M ago
Ascendis Pharma initiated with a Buy at Stifel
PremiumThe FlyAscendis Pharma initiated with a Buy at Stifel
2M ago
Ascendis Pharma to spotlight latest updates for TransCon portfolio at ENDO 2024
PremiumThe Fly
Ascendis Pharma to spotlight latest updates for TransCon portfolio at ENDO 2024
2M ago
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
PremiumPress Releases
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
2M ago
Ascendis says TransCon PTH PDUFA target action date extended three months
PremiumThe FlyAscendis says TransCon PTH PDUFA target action date extended three months
2M ago
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
PremiumPress Releases
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
2M ago
Ascendis announces 2-year results from post-hoc analysis of Phase 3 trial
PremiumThe Fly
Ascendis announces 2-year results from post-hoc analysis of Phase 3 trial
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100